Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Deutsche Bank AG — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Deutsche Bank AG trades at $35.72 (market cap $68.30B). The key difference: Deutsche Bank AG is the larger of the two by market cap, and Deutsche Bank AG pays a 3.25% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DB | |
|---|---|---|
Market Cap | $39.89B | $68.30B |
Sector | Health | Financials |
52-Week High | $491.22 | $40.33 |
52-Week Low | $278.09 | $28.37 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Deutsche Bank (DB) trades at $35.77, up 1.05% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $1.24 versus $1.15, and net income margin improving to 21.98% in 2025. Recent news includes expansion into Saudi Arabia and a dividend of $1.00 payable in June 2026, reflecting strategic growth initiatives.
Outlook is cautiously optimistic given low P/E of 9.94 and P/B of 0.77, suggesting undervaluation, but risks include volatile cash flows with a net outflow of $33.10B in 2024 and mixed analyst sentiment with only 21% buy ratings. Investors should weigh earnings consistency against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
